- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
- Posted By: TreehillPartners
- In: Dealmaking, Financing & Capital Markets
A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking
The start of a new year in healthcare has over the past decades been characterized by back-to-back meetings spread across hotel rooms in San Francisco where the industry’s annual gathering had taken place, not to say had been celebrated. Nobody knows if or when we will return to holding physical meetings. What the pandemic has shown us all is that a lot of time can be saved when interacting virtually:
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Drug Development, Strategy & Corporate Development
In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.While the gardener knows that the autumn harvest will be stronger for doing it, the thinning out process is painful every time...
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Drug Development, Strategy & Corporate Development
For most emerging bio-pharma or medtech companies, establishing a development or commercialization partnership is a core component of their strategic plan, and, sealing the deal is cause for much celebration. While hard work and a number of all-nighters may go into signing an agreement, ensuring the partnership achieves its objectives and sails across the finish line is often harder, and often a bumpy ride...
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Drug Development, Strategy & Corporate Development
The majority of pharma and biotech venture creations are aimed at one or both of two fundamental objectives, bringing a novel therapeutic to patients and generating returns for their founders and investors. Often, pathways are poorly understood by the bootstrap team, and professional “help” is being sought from incubators, boards, investors and advisors, embedding possibly conflicting perspectives and goals into the core fabric of the company.